A Phase IIIb, Prospective, Interventional, Multicentre, 3-year Study to Explore the Long-term Evolution of Sign and Symptoms, and Occurence of Complications in Dry Eye Patients With Severe Keratitis Receiving Ikervis (1mg/mL Ciclosporin)
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes; Keratitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Santen S.A.S.
Most Recent Events
- 28 Aug 2024 Primary endpoints of safety removed after result submission, hence focus of study becomes TU only.
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 29 Aug 2023 The trial has been completed in Poland, according to an European Clinical Trials Database.